Frazier Life Sciences IX is a Venture Capital Fund in Washington, that has raised $418.93 mm from 55 investors, for a fund started in Oct 2017. Data from SEC filing on 31 Oct 2017.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry
SEC CIK
AUM ?
$756.28 mm
Address
Frazier Life Sciences IX
601 UNION STREET
SUITE 3200
SEATTLE
WA 98101
601 UNION STREET
SUITE 3200
SEATTLE
WA 98101
Phone
206-254-7200
Ownership
Fund structure | AUM | Fund type |
---|---|---|
Frazier Life Sciences Management, LP | $4.04 bn | |
Frazier Healthcare Vii-a, L.P. | $63.47 mm | Private Equity Fund |
Frazier Healthcare VII, L.P. | $218.28 mm | Private Equity Fund |
Frazier Life Sciences IX, L.P. | $756.28 mm | Venture Capital Fund |
Frazier Life Sciences Public Fund, L.P. | $996.41 mm | Private Equity Fund |
Frazier Life Sciences VIII, L.P. | $372.19 mm | Venture Capital Fund |
Frazier Life Sciences X, L.P. | $642.06 mm | Venture Capital Fund |
Frazier Life Sciences XI, L.P. | $987.24 mm | Venture Capital Fund |
Latest filings (excl ownership)
Latest ownership filings
SC 13D/A
Mirum Pharmaceuticals, Inc.
5 Sep 23
SC 13D/A
Passage BIO, Inc.
15 Jun 23
SC 13D/A
Mirum Pharmaceuticals, Inc.
14 Apr 23
SC 13D/A
Phathom Pharmaceuticals, Inc.
26 Sep 22
SC 13D/A
Mirum Pharmaceuticals, Inc.
16 Aug 22
SC 13D/A
Passage BIO, Inc.
15 Aug 22
SC 13D/A
Phathom Pharmaceuticals, Inc.
11 Aug 22
SC 13G/A
Tarsus Pharmaceuticals, Inc.
28 Jan 22
SC 13G/A
Krystal Biotech, Inc.
4 Feb 21
SC 13D/A
Passage BIO, Inc.
27 Jan 21